ReviewWiley interdisciplinary reviews. Systems biology and medicine
Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms.
Review in Wiley interdisciplinary reviews. Systems biology and medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Computational Advances in Drug Safety: Systematic and Mapping Review of Knowledge Engineering Based Approaches.Frontiers in pharmacology · 2019Pooled it
- An interpretable machine learning framework for adverse drug reaction prediction from drug-target interactions.PloS one · 2026Article
- Machine Learning Techniques for Predicting Drug-Related Side Effects: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2024Article
- A patient safety knowledge graph supporting vaccine product development.BMC medical informatics and decision making · 2024Article
- Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems.Frontiers in drug safety and regulation · 2023Review
- Machine learning prediction of side effects for drugs in clinical trials.Cell reports methods · 2022Article
- Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database.Drugs - real world outcomes · 2022Article
- Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.CPT: pharmacometrics & systems pharmacology · 2022Review
- Bioinformatics Accelerates the Major Tetrad: A Real Boost for the Pharmaceutical Industry.International journal of molecular sciences · 2021Review
- Investigating ADR mechanisms with Explainable AI: a feasibility study with knowledge graph mining.BMC medical informatics and decision making · 2021Article
- Emerging approaches to polypharmacy among older adults.Nature aging · 2021Review
- Drug-target-ADR Network and Possible Implications of Structural Variants in Adverse Events.Molecular informatics · 2020Article
- Towards the routine use of in silico screenings for drug discovery using metabolic modelling.Biochemical Society transactions · 2020Review
- Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data.Medicina (Kaunas, Lithuania) · 2019Article
- Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study.BMJ open · 2019Observational
- Adverse Event Circumstances and the Case of Drug Interactions.Healthcare (Basel, Switzerland) · 2019Article
- Examining Socioeconomic and Computational Aspects of Vaccine Pharmacovigilance.BioMed research international · 2019Article
- PathFX provides mechanistic insights into drug efficacy and safety for regulatory review and therapeutic development.PLoS computational biology · 2018Article
- Article
- Biomarkers of adverse drug reactions.Experimental biology and medicine (Maywood, N.J.) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Small molecules are indispensable to modern medical therapy. However, their use may lead to unintended, negative medical outcomes commonly referred to as adverse drug reactions (ADRs). These effects vary widely in mechanism, severity, and populations affected, making ADR prediction and identification important public health concerns. Current methods rely on clinical trials and postmarket surveillance programs to find novel ADRs; however, clinical trials are limited by small sample size, whereas postmarket surveillance methods may be biased and inherently leave patients at risk until sufficient clinical evidence has been gathered. Systems pharmacology, an emerging interdisciplinary field combining network and chemical biology, provides important tools to uncover and understand ADRs and may mitigate the drawbacks of traditional methods. In particular, network analysis allows researchers to integrate heterogeneous data sources and quantify the interactions between biological and chemical entities. Recent work in this area has combined chemical, biological, and large-scale observational health data to predict ADRs in both individual patients and global populations. In this review, we explore the rapid expansion of systems pharmacology in the study of ADRs. We enumerate the existing methods and strategies and illustrate progress in the field with a model framework that incorporates crucial data elements, such as diet and comorbidities, known to modulate ADR risk. Using this framework, we highlight avenues of research that may currently be underexplored, representing opportunities for future work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.